GlobeNewswire by notified

Novo Nordisk's sales increased by 25% in Danish kroner and by 16% at constant exchange rates to DKK 83.3 billion in the first six months of 2022

Share

3 August 2022  - Financial report for the period 1 January 2022 to 30 June 2022

  • Operating profit increased by 26% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 37.5 billion.
  • Sales in International Operations increased by 15% in Danish kroner (10% at CER), and sales in North America Operations increased by 36% in Danish kroner (24% at CER).
  • Sales within Diabetes and Obesity care increased by 28% in Danish kroner to DKK 72.7 billion (19% at CER), mainly driven by GLP-1 diabetes sales growth of 57% in Danish kroner (45% at CER). Rare disease sales increased by 6% measured in Danish kroner (unchanged at CER).
  • Obesity care sales grew by 99% in Danish Kroner (84% at CER). Novo Nordisk expects to make all Wegovy® dose strengths available in the US towards the end of 2022.
  • Within R&D, Novo Nordisk has now successfully completed five phase 3a trials with insulin icodec, a long-acting once-weekly insulin. Based on a recommendation from an independent Data Monitoring Committee following an interim analysis, the SELECT cardiovascular outcomes trial continues in accordance with the trial protocol.
  • For the 2022 outlook, sales growth is now expected to be 12-16% at CER and operating profit growth is now expected to be 11-15% at CER. Sales and operating profit growth reported in Danish kroner are now expected to be 9 and 14 percentage points higher than at CER, respectively.
PROFIT AND LOSSH1 2022H1 2021Growth
as reported
Growth
at CER*
DKK million
Net sales83,29666,84525%16%
Operating profit37,53829,76126%14%
Net profit27,52824,74611%N/A
Diluted earnings per share (in DKK)12.0810.7113%N/A

* CER: Constant exchange rates (average 2021).

Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the sales growth in the first half of 2022. The growth is driven by increasing demand for GLP-1 based diabetes treatments, especially Ozempic®. Our obesity treatments are also contributing to growth as more people living with obesity are being treated and the Obesity care market continues to expand. The performance in the first six months has enabled us to raise our outlook for the full year."

On 3 August 2022 at 19.30 CEST, corresponding to 1.30 pm EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Financial calendar
2 November 2022Financial statement for the first nine months of 2022
1 February 2023Financial statement for 2022


Contacts for further information
Media:
Ambre Brown Morley+45 3079 9289abmo@novonordisk.com
Natalia Salomao Abrahao (US)+1 848 304 1027niaa@novonordisk.com
Investors:
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted+45 3077 6915dhel@novonordisk.com
Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com
Mark Joseph Root (US)+1 848 213 3219mjhr@novonordisk.com

Company announcement No 61 / 2022

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sampo plc: Managers’ Transactions (Wahlroos/Alectoris AS)3.10.2022 08:55:00 CEST | Press release

SAMPO PLC MANAGERS’ TRANSACTIONS 3 October 2022 at 9:55 am Sampo plc: Managers’ Transactions (Wahlroos/Alectoris AS) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation. The transaction concerns the change of ownership in Alectoris AS. After the transaction, Wahlroos doesn’t have controlling interest in Alectoris AS. ____________________________________________ Person subject to the notification requirement Name: Björn Wahlroos Position: Member of the Board/Deputy member Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: INITIAL NOTIFICATION Reference number: 20225/5/4 ____________________________________________ Transaction date: 2022-09-27 Venue not applicable Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: GIFT, DONATION OR INHERITANCE (MADE) Transaction details (1): Volume: 570,000 Unit price: 0 N/A Aggregated transactions (1): Volume: 570,000 Volume weighted average price: 0 N/

Norsk Hydro: Status share buyback program3.10.2022 08:10:00 CEST | Press release

Please see below information about transactions made under the share buy-back program for Norsk Hydro ASA. Announcement date of the share buyback program: September 23, 2022 End date of the share buyback program: March 29, 2023 Overview of transactions: Date Aggregate daily volume (no. of shares) Volume weighted average price (NOK) Total transaction value (NOK) 26.09.2022177 00055.919 895 23827.09.2022170 00057.779 820 30528.09.2022178 00055.879 945 44729.09.2022170 00057.679 803 52630.09.2022170 00058.539 950 746Total transactions under the program:865 00057.1349 415 263 Following the above listed transactions, Norsk Hydro ASA owns a total of 17 317 403 shares, corresponding to 0.84% of Norsk Hydro ASA's share capital. Attachment: An overview of all the completed transactions under the program for the dates specified above is attached to this notification and available on www.newsweb.no. This is information that Norsk Hydro ASA is obliged to make public pursuant to the EU Market Abuse

Norsk Hydro: Status tilbakekjøp av egne aksjer3.10.2022 08:10:00 CEST | Pressemelding

Nedenfor er informasjon om transaksjoner foretatt under tilbakekjøpsprogrammet for Norsk Hydro ASA. Dato for når tilbakekjøpsprogrammet ble annonsert: 23. september 2022 Tilbakekjøpsprogrammets varighet: 29. mars 2023 Oversikt over transaksjoner: Date Aggregate daily volume (no. of shares) Volume weighted average price (NOK) Total transaction value (NOK) 26.09.2022177 00055,919 895 23827.09.2022170 00057,779 820 30528.09.2022178 00055,879 945 44729.09.2022170 00057,679 803 52630.09.2022170 00058,539 950 746Total transactions under the program:865 00057,1349 415 263 Etter gjennomføringen av overnevnte transaksjoner, eier Norsk Hydro ASA totalt 17 317 403 egne aksjer, tilsvarende 0,84% av Norsk Hydro ASAs aksjekapital. Vedlegg: En oversikt over alle gjennomførte handler under tilbakekjøpsprogrammet som er uført i overnevnte tidsperiode er vedlagt denne meldingen og tilgjengelig på www.newsweb.no. Denne opplysningen er informasjonspliktig i henhold til EUs Market Abuse Regulation og krav

Sampo plc’s share buybacks 30/09/20223.10.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 03/10/2022 at 08:30 am Sampo plc’s share buybacks 30/09/2022 On 30/09/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)13,80843.79AQEU25,54143.80CEUX11,97643.85TQEX89,53443.80XHELTOTAL140,85943.80 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 10,853,632 Sampo A shares representing 2.04 per cent of the total number of shares in Sampo plc. Details of

Bavarian Nordic Enters Agreement with Country in Latin America on the Supply of Monkeypox Vaccines3.10.2022 07:30:00 CEST | Press release

First country in Latin America to sign a bilateral supply agreement thus expanding access to the monkeypox vaccine beyond the availability of vaccines through PAHOAdditional supply agreement also signed with PAHO to expand availability for its member countries COPENHAGEN, Denmark, October 3, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today an agreement with a Latin American country for the supply of the Company’s monkeypox vaccine. This is the Company’s first bilateral supply agreement for the vaccine in Latin America, outside the scope of the agreement entered with the Pan American Health Organization (PAHO) in August 2022, which has enabled access to the vaccine for its member countries. Through PAHO’s Revolving Fund for Access to Vaccines, the country will get access to its first monkeypox vaccines later this month and deliveries under the bilateral agreement will start in December 2022. Separately, following the initial supply agreement in August, PAHO has requested additiona